Neurogene develops life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases.

Register for Details

For more details on financing and valuation for Neurogene, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Neurogene

Forge green plus iconForge green minus icon

What is Neurogene's IPO price?

Neurogene's IPO price is $30.19 as of 1/18/24.
Forge green plus iconForge green minus icon

What is Neurogene's funding to date?

Neurogene has raised $183.58MM to date.
Forge green plus iconForge green minus icon

When was Neurogene founded?

Neurogene was founded in 2018.

Neurogene Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
12/16/2020 Series B $115MM raised $XXX.XX $XXX.XX
2/12/2019 Series A-1 and A-2 $68.58MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Nov 15, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.